CAN LARGE LANGUAGE MODELS SIMULATE HTA COMMITTEE DISCUSSIONS? FINDINGS AND CHALLENGES FROM A CASE STUDY IN NEOADJUVANT TREATMENT OF RESECTABLE NON-SMALL CELL LUNG CANCER

被引：0
|
作者：
Reason, T. [1 ]
Klijn, S. [2 ]
Gimblett, A. [1 ]
Malcolm, B. [3 ]
机构：
[1] Estima Sci Ltd, London, England
[2] Bristol Myers Squibb, Utrecht, ZH, Netherlands
[3] Bristol Myers Squibb, London, Middx, England
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
P46
引用
收藏
页码：S11 / S11
页数：1
相关论文
共 50 条
  • [41] Neoadjuvant immunochemotherapy of pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
    Chen, Y.
    Yan, B.
    You, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S108 - S109
  • [42] Progress on neoadjuvant immunotherapy in resectable non-small cell lung cancer and potential biomarkers
    Wu, Xinyu
    Chau, Yi Fung
    Bai, Hua
    Zhuang, Xiaofei
    Wang, Jie
    Duan, Jianchun
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [43] Surgical Outcomes After Neoadjuvant Chemoimmunotherapy for Resectable Non-Small Cell Lung Cancer
    Hu, Yan
    Ren, Si-Ying
    Wang, Ruo-Yao
    Zeng, Chao
    Li, Ji-Na
    Xiao, Peng
    Wu, Fang
    Yu, Feng-Lei
    Liu, Wen-Liang
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [44] Surgery after neoadjuvant immunotherapy in patients with resectable non-small cell lung cancer
    Huynh, Caroline
    Walsh, Logan A.
    Spicer, Jonathan D.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) : 563 - 580
  • [45] Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy
    Ryan D. Gentzler
    David O. Riley
    Linda W. Martin
    Current Oncology Reports, 2020, 22
  • [46] Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy
    Gentzler, Ryan D.
    Riley, David O.
    Martin, Linda W.
    CURRENT ONCOLOGY REPORTS, 2020, 22 (11)
  • [47] Neoadjuvant therapy in non-small cell lung cancer: basis, promise, and challenges
    Kalvapudi, Sukumar
    Vedire, Yeshwanth
    Yendamuri, Sai
    Barbi, Joseph
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [48] A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer
    Cascone, Tina
    Sepesi, Boris
    Lin, Heather Y.
    Kalhor, Neda
    Parra, Edwin R.
    Jiang, Mei
    Godoy, Myrna C. B.
    Zhang, Jianjun
    Fossella, Frank, V
    Tsao, Anne S.
    Lam, Vincent K.
    Lu, Charles
    Mott, Frank E.
    Simon, George R.
    Antonoff, Mara B.
    Mehran, Reza J.
    Rice, David C.
    Behrens, Carmen
    Weissferdt, Annikka
    Moran, Cesar
    Vaporciyan, Ara A.
    Lee, J. Jack
    Swisher, Stephen G.
    Gibbons, Don L.
    Wistuba, Ignacio I.
    William, William N., Jr.
    Heymach, John, V
    CLINICAL CANCER RESEARCH, 2020, 26 (14) : 3525 - 3536
  • [49] An open, observational clinical study of neoadjuvant therapy in resectable stage III non-small cell lung cancer
    Qi, Yuwen
    Gu, Linping
    Shen, Jie
    Yao, Yaxian
    Zhao, Yi
    Lu, Shun
    Chen, Zhiwei
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [50] Challenges and controversies in resectable non-small cell lung cancer: a clinician's perspective
    Houda, Ilias
    Dickhoff, Chris
    Uyl-de Groot, Carin A.
    Damhuis, Ronald A. M.
    Reguart, Noemi
    Provencio, Mariano
    Levy, Antonin
    Dziadziuszko, Rafal
    Pompili, Cecilia
    Di Maio, Massimo
    Thomas, Michael
    Brunelli, Alessandro
    Popat, Sanjay
    Senan, Suresh
    Bahce, Idris
    LANCET REGIONAL HEALTH-EUROPE, 2024, 38
12345